1. Home
  2. CFBK vs NERV Comparison

CFBK vs NERV Comparison

Compare CFBK & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CF Bankshares Inc.

CFBK

CF Bankshares Inc.

HOLD

Current Price

$30.11

Market Cap

178.1M

Sector

Finance

ML Signal

HOLD

NERV

Minerva Neurosciences Inc

HOLD

Current Price

$4.28

Market Cap

210.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CFBK
NERV
Founded
1892
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
178.1M
210.1M
IPO Year
2005
2014

Fundamental Metrics

Financial Performance
Metric
CFBK
NERV
Price
$30.11
$4.28
Analyst Decision
Buy
Buy
Analyst Count
2
2
Target Price
$31.50
$10.50
AVG Volume (30 Days)
44.0K
117.8K
Earning Date
05-08-2026
05-01-2026
Dividend Yield
1.23%
N/A
EPS Growth
30.58
N/A
EPS
0.77
N/A
Revenue
N/A
$41,175,600.00
Revenue This Year
$31.99
N/A
Revenue Next Year
$9.09
N/A
P/E Ratio
$38.83
N/A
Revenue Growth
N/A
N/A
52 Week Low
$22.10
$1.57
52 Week High
$34.34
$12.46

Technical Indicators

Market Signals
Indicator
CFBK
NERV
Relative Strength Index (RSI) 58.84 32.13
Support Level $28.40 $3.69
Resistance Level $30.25 $4.59
Average True Range (ATR) 0.91 0.37
MACD 0.09 -0.02
Stochastic Oscillator 54.13 15.00

Price Performance

Historical Comparison
CFBK
NERV

About CFBK CF Bankshares Inc.

CF Bankshares Inc is engaged in the provision of a variety of financial services. It provides personalized business banking products and services, including commercial loans and leases, commercial and residential real estate loans, equipment leasing, SBA loans, and treasury management depository services. The revenues are derived principally from the interest and fees on loans originated and noninterest income generated on the sale of loans.

About NERV Minerva Neurosciences Inc

Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.

Share on Social Networks: